Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that PCOS is a complex disorder caused by both genetic and environmental factors, affecting women's health in various ways, and requires personalized treatment.

Insulin resistance and obesity are key factors in the development and worsening of polycystic ovary syndrome, and lifestyle changes are important for managing it.

Male pattern baldness involves genetics, hormones, and needs better treatments.

Hormone therapy is essential for transgender individuals but requires careful management due to possible metabolic effects.

Insulin sensitizers may slightly reduce hirsutism but are less effective than other treatments.

Oxidative stress affects hair loss in men with androgenetic alopecia.

Activating the Wnt/β-catenin pathway could lead to new hair loss treatments.

The conclusion is that managing androgen excess requires long-term treatment, including hormonal contraceptives and androgen blockers, with follow-up after six months.

Effective hair loss treatment in women requires correct diagnosis and can include medications like minoxidil, antiandrogens, and treatments for underlying conditions like PCOS.

Hormonal treatments can help with acne, especially in women, by lowering androgen levels or blocking their effects.

Lifestyle changes improve metabolism and fertility in overweight PCOS patients; anti-obesity drugs show potential but need more research.

Blocking the enzyme 11β-HSD1 might help treat obesity and metabolic issues.

Improving insulin sensitivity and weight loss can help manage polycystic ovary syndrome (PCOS).

PCOS is often linked to insulin resistance and obesity, and weight loss can improve symptoms.

Fadrozole and finasteride change gene expression related to sex hormones and thyroid hormones in frog larvae development.

Oral contraceptives help treat hyperandrogenic disorders, improving symptoms like excessive hair and acne.

Finasteride can reduce fertility in some men, but stopping it increases sperm count.

Men with early hair loss have similar hormone levels to women with PCOS, possibly increasing risk of obesity and heart issues.

Inhibitors of 11β-HSD1 show potential for treating type 2 diabetes but require more testing for safety and effectiveness.

The conclusion is that oral contraceptives and antiandrogens can treat hirsutism and acne in women with cutaneous hyperandrogenism, but more research is needed for effective treatments, especially for hair loss.

Male hormones, or androgens, affect women's health in areas like mood and bone density, and hormone replacement therapy using antiandrogenic progestogens can improve mood disorders and alertness in menopausal women.

Minoxidil helps hair regrowth in traction alopecia.

Improved Finasteride delivery for hair loss treatment.

Nanoparticles with more oleic acid improved the delivery and stability of the drug spironolactone.

A dietary supplement with Boswellia serrata, Curcuma longa, and Vitis vinifera showed potential improvement in hair health for telogen effluvium patients, but more research is needed.

PPCM microspheres allow controlled finasteride release over 24 hours.

Dihydrotestosterone can be made from dehydroepiandrosterone in skin cells without needing testosterone.

Cell-based therapies using dermal papilla cells and adipocyte lineage cells show potential for hair regeneration.

Androgens may influence T cells, contributing to higher autoimmune liver disease risk in women.

FPHL common in Taiwanese women; risk factors include BMI, high glucose, early puberty, fewer childbirths, oral contraceptives, and UV exposure.